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In this study, in vitro blood biocompatibility of Mg-Nd-Zn-Zr (JDBM) alloy was investigated to determine its suitability as a de-
gradable medical biomaterial. Blood biocompatibility was assessed by blood cell aggregation, platelet adhesion, and protein ad-
sorption. A titanium alloy was used as control. The results showed that the JDBM alloy did not induce significant blood cell ag-
gregation, platelet adhesion, and protein adsorption comparison with the titanium alloy (P>0.05). Our data indicate that the JDBM 
alloy has excellent in vitro blood compatibility, and thus can be considered as a potential degradable biomaterial for medical ap-
plications with respect to hemocompatibility. 
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In recent years, there has been renewed interest in magne-
sium alloys, which are easily corroded in solutions, espe-
cially in the presence of chloride ions. Indeed, magnesium 
alloys have become promising degradable biomaterials 
[1–6]. Recent studies have revealed that magnesium alloys 
have good biocompatibility, may promote osteocyte growth, 
and may induce production of osteoblasts and osteocytes 
[7–10]. Owing to suitable mechanical properties and good 
biocompatibility, degradable magnesium alloys can be uti-
lized in many clinical situations, such as bone repair and 
tissue engineering scaffolds; however, the rapid rate of cor-
rosion and the appearance of gas bubbles in the physiologic 
environment impose severe limitations which have pre-
vented further clinical applications. Hence, to utilize a 
magnesium alloy for clinical implantation, corrosion re-
sistance must be improved. 
Alloying, an effective and convenient method, has 
emerged as a strategy to enhance the corrosion resistance of 
magnesium [11]. To improve corrosion resistance and bio-
compatibility of magnesium, a novel patent magnesium 
alloy (Mg-3Nd-0.2Zn-0.4Zr; wt.%, denoted Shanghai JiaoDa 
BioMg alloy, abbreviated as JDBM) has been designed in 
our laboratory by the addition of neodymium, zinc, and zir-
conium to magnesium [12]. In a previous study, we focused 
on the microstructure [12] and biological properties of the 
JDBM alloy, revealing that the JDBM alloy has good bio-
compatibility in vitro [13]. However, the blood compatibil-
ity of the JDBM alloy has not been systematically studied in 
vitro and in vivo. 
In the current study we focused on the in vitro blood 
compatibility of the JDBM alloy, and characterized the in 
vitro blood biocompatibility of the JDBM alloy because the 
degradation products of the JDBM alloy are absorbed into 
the bloodstream during the degradation process. It is ex-
pected that this work may help to confirm the in vitro blood 
biocompatibility of the JDBM alloy and obtain a new 
promising degradable magnesium alloy. 
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1  Materials and methods 
1.1  Materials  
The JDBM alloy was obtained from the National Engineer-
ing Research Center of Light Alloy Net Forming, Shanghai 
Jiao Tong University. Titanium alloy (Ti-6Al-4V (control)), 
which is usually used in orthopedics and has good biocom-
patibility, was obtained from Shanghai Puwei Medical In-
strument Factory Co., Ltd. (Shanghai, China). The compo-
sition of the JDBM and titanium alloys is listed in Tables 1 
and 2, respectively. 
The JDBM alloy was prepared in a mild steel crucible 
under the protection of a mixed gas consisting of SF6 and 
CO2. Pure Mg (99.99%) was melted in the steel crucible, 
with pure Zn (99.995%) added at a temperature of 700– 
710°C, then Nd, Zr was added as Mg-25Nd and Mg-30Zr 
master alloys at a temperature of 740–760°C [12]. 
The JDBM and titanium alloys were formed into discs 
(10 mm in diameter and 2 mm height); the discs were 
ground with abrasive paper, polished with diamond abrasive 
paste, followed by ultrasound washing in ethanol for 10 min, 
and sterilizing with ethylene oxide. 
New Zealand white rabbits, clean grade and weighing 
(2.5±0.3) kg, were supplied by the Shanghai Jiesijie Lab 
Animal Co., Ltd. (Shanghai, China; license No. SCXK [hu] 
2010-0026). All experimental animals were treated hu-
manely in accordance with the Guidance Suggestions for 
the Care and Use of Laboratory Animals issued by the Min-
istry of Science and Technology of the People’s Republic of 
China (2006-09-30). 
The study was approved by the Ethics Committee of the 
Sixth People’s Hospital of Shanghai Jiao Tong University.  
1.2  Microstructure of JDBM alloy 
The microstructure of the JDBM alloy was characterized 
using a metallurgical microscope (4XI; Shanghai Precise 
Science Instrument Company, Shanghai, China). The mor-
phology of the JDBM alloy was characterized using scan-
ning electron microscopy (SEM, Hitachi S-4800, Japan). 
1.3  Blood cell aggregation 
Aggregation of blood cells, including red blood corpuscles 
(RBCs), white blood corpuscles (WBCs), and platelets, was 
evaluated using the blood cell count method. Arterial blood 
(3 mL) from a healthy New Zealand white rabbit was col-
lected into a conical tube that contained 0.5 mL of potassi-
um oxalate (20 g/L) anticoagulant. Then, the JDBM alloy 
disc (test group) and titanium alloy disc (control group) 
were immediately immersed in blood. The number of RBCs, 
WBCs, and platelets were measured using an automatic 
hematology analyzer (Sysmex, XT-1800i, Japan) before and 
8 min after the disc was immersed in blood [14]. Six paral-
lel samples were evaluated in each group. 
1.4  Platelet adhesion 
Arterial blood (8 mL) was obtained from a healthy New 
Zealand white rabbit. Platelet-rich plasma (PRP) was gener-
ated by centrifuging the fresh blood at a rate of 2500 r/min 
for 5 min, and PRP was collected into a new tube. The PRP 
was overlaid atop the JDBM and titanium alloy discs and 
incubated at 37°C for 1 h. The discs were rinsed with phos-
phate buffer solution to remove the non-adherent platelets. 
The adherent platelets were fixed using 2.5% glutaralde-
hyde for 1 h at room temperature, then dehydrated with a 
gradient immersion in 50%, 60%, 70%, 80%, 90%, and 
100% ethanol for 10 min each. The discs were subjected to 
critical point drying and gold sputtering. Then, the surface 
of the JDBM and titanium alloy disc-attached platelets were 
observed by SEM. Five different fields were randomly 
counted and the values are expressed as the average number 
of adherent platelets per disc [15]. Six parallel samples were 
evaluated in each group. 
1.5  Protein adsorption  
Arterial blood (3 mL) from a healthy New Zealand white 
rabbit was collected into a conical tube that contained 0.5 
mL of potassium oxalate (20 g/L) anticoagulant. Then, the 
JDBM alloy disc (test group) and titanium alloy disc (con-
trol group) were immediately immersed in blood. The total 
protein of plasma was measured using an automatic blood 
biochemistry analyzer (Hitachi 7600-020, Japan) before and 
8 min after the disc was immersed in blood [14]. Six paral-
lel samples were evaluated in each group. 
1.6  Statistic analysis 
Statistical analysis was performed with SPSS 13.0 (SPSS, 
Inc., Chicago, IL, USA) to evaluate the differences in each 
group; all data were expressed as the mean±SD. The ex-
perimental values were analyzed using a Student’s t-test. 
The statistical significance was defined as a P<0.05. 
Table 1  Chemical composition of the JDBM alloy  
Materials 
Chemical composition (wt.%) 
Mg Nd Zn Zr Si Ni Cu Fe 
JDBM alloy Balance 2.83 0.20 0.44 0.018 0.0025 0.0195 0.0057 
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Table 2  Chemical composition of the titanium alloy  
Materials 
Chemical composition (wt.%) 
Ti Al V Fe N O C H 
Titanium alloy  Balance 6.05 4.13 0.064 0.012 0.10 0.01 0.0037 
 
 
2  Results 
2.1  Microstructure and morphology of the JDBM alloy 
As shown in Figure 1(c), a typical metallurgical micro-
structure of the JDBM alloy, the grain boundaries were 
barely recognizable due to the more homogeneous micro-
structure of the JDBM alloy. Therefore, alloying can re-
markably change the microstructure of the JDBM alloy, 
which could improve the corrosion resistance and cause a 
different degradation behavior. The SEM morphology of the 
JDBM alloy in Figure 1(d) illustrates the uniform distribu-
tion of all particulates within the JDBM alloy. 
2.2  Blood cell aggregation 
The aggregation of blood cells on the surfaces of the JDBM 
and titanium alloy samples is shown in Figures 2–4. As 
shown in Figure 2(a), the reduction in RBC aggregation to 
the JDBM and titanium alloys was 19.9% and 29.2%, re-
spectively. There was no significant RBC aggregation on 
the JDBM alloy compared with the titanium alloy (P>0.05). 
The reduction in WBC aggregation to the JDBM and tita-
nium alloys was 31.21% and 27.8%, respectively (Figure 
3(a)). There was no significant aggregation of WBCs occur-
ring in the test group compared with the control group 
(P>0.05). As shown in Figure 4(a), the reduction in platelet 
aggregation to the JDBM and titanium alloys was 19.0% 
and 18.9%, respectively. There was no significant platelet 
aggregation to the JDBM alloy compared with the titanium 
alloy (P>0.05). These results indicate that blood cells sus-
pended in the JDBM alloy did not aggregate due to the  
 
 
Figure 1  (a), (b) Photographs of the JDBM alloy disc. (c) Metallurgical 
microstructure and (d) SEM morphology of the JDBM alloy. 
 
Figure 2  (a) The reduction in RBC aggregation to the JDBM alloy and 
titanium alloy. (b) Comparison of aggregation of RBCs on the surface of 
the JDBM alloy and titanium alloy (*P＞0.05). 
 
Figure 3  (a) The reduction in WBC aggregation to the JDBM alloy and 
titanium alloy. (b) Comparison of aggregation of WBCs on the surface of 
the JDBM alloy and titanium alloy (*P>0.05). 
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Figure 4  (a) The reduction in platelet aggregation to the JDBM and 
titanium alloys. (b) Comparison of aggregation of platelets on the surfaces 
of the JDBM and titanium alloys (*P>0.05). 
excellent blood compatible behavior.  
2.3  Platelet adhesion 
The platelets adherent to the JDBM and titanium alloy discs 
were observed via SEM. There was a small quantity of 
platelets adherent to the surfaces of the JDBM and titanium 
alloy discs. The morphologies of adherent platelets were 
characterized, which showed that platelets were nearly 
round in the test group with only one or two short pseudo-
podia spreading on the surface of the titanium alloy discs 
(Figure 5). Figure 6 illustrates the number of platelets ad-
herent to the JDBM and titanium alloy discs after incuba-
tion in PRP for 1 h. There was no significant platelet adhe-
sion to the JDBM alloy compared with the titanium alloy 
(P>0.05). 
2.4  Protein adsorption 
As shown in Figure 7(a), the reduction in protein adsorption  
  
 
Figure 5  SEM images showing platelet adhesion on the surface of (a) the 
JDBM and (b) titanium alloy samples. 
 
Figure 6  Comparison of platelet adhesion on the surface of the JDBM 
and titanium alloy samples (*P>0.05). 
 
Figure 7  Comparison of protein adsorption on the surface of (a) the 
JDBM and (b) titanium alloy samples (*P>0.05).  
to the JDBM and titanium alloys was 3.19% and 3.32%, 
respectively. There was no significant change in total pro-
tein before and after the disc immersed in blood for 8 min in 
the test and control groups, indicating no significant adsorp-
tion of protein occurring in the test group compared with the 
control group (P>0.05). 
3  Discussion 
Materials used for medical device fabrication must have 
good biocompatibility because the materials will directly 
contact tissues and cells after implantation in the human 
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body. Specifically, the blood compatibility of these materi-
als is a crucial factor because that contact between materials 
and blood causes blood cell activation and adhesion, fol-
lowed by blood coagulation. Concurrently, the activated 
blood cells release inflammatory cytokines, resulting in 
damage of the local tissues and cells. As a new degradable 
medical biomaterial, it is important to evaluate the blood 
biocompatibility of the JDBM alloy from experimental 
studies prior to clinical application because the degradation 
products are absorbed into the bloodstream when the JDBM 
alloy is degrading in the human body. Blood is a complex 
living system. The response of blood to a material is deter-
mined by the following three primary factors: state of the 
blood; flow velocity; and the surface [16]. According to an 
expanded, practical definition of blood compatibility [17], a 
material can be evaluated using the effects of the material 
on erythrocytes, leukocytes, and platelets. If a material does 
not damage blood components upon contact, the material is 
defined as a blood-compatible material [18]. 
In the current study we focused on the blood compatibil-
ity of the JDBM alloy when used as a medical implant. 
Most importantly, the blood cell aggregation studies were 
carried out to confirm the blood compatibility of the JDBM 
alloy. The results showed that the reduction in RBC aggre-
gation to the JDBM and titanium alloys was 19.9% and 
29.2%, respectively. There was no significant RBC aggre-
gation to the JDBM alloy compared with the titanium alloy 
(P>0.05). The reduction in WBC aggregation to the JDBM 
and titanium alloys was 31.21% and 27.8%, respectively. 
There was no significant aggregation of WBCs occurring in 
the test group compared with the control group (P>0.05). 
The reduction in platelet aggregation to the JDBM and tita-
nium alloys was 19.0% and 18.9%, respectively. There was 
no significant platelet aggregation to the JDBM alloy com-
pared with the titanium alloy (P>0.05). These results indi-
cate that blood cells suspended in the JDBM alloy did not 
aggregate due to blood-compatible behavior.  
The initial event when a material comes in contact with 
blood is adsorption of proteins. Protein adsorption triggers 
the activation of blood cells and blood coagulation on mate-
rial surfaces through a complex series of events, including 
the activation of platelets, leukocytes, complement, and the 
fibrinolytic system [19]. Therefore, the hemocompatibility 
of the JDBM alloy was confirmed again using a protein 
adsorption and platelet adhesion assay. Platelets that are 
altered by contacting a material may hasten thrombosis by 
adhering to the surface of the material and releasing or 
making available to the blood constituents, such as platelet 
factor 4. Concurrently, damaged erythrocytes may release 
hemoglobin and other cellular components, including 
thromboplastic substances and adenosine diphosphate, 
which is a known agonist of platelet activation. Leukocytes, 
when damaged, may also release materials which influence 
coagulation and platelets. In the present study platelets ad-
hered to the JDBM alloy did not appear activated based on 
the round shape (Figure 5) compared with the platelets ad-
herent to the titanium alloy. As shown in Figure 6, the 
number of platelets adherent to the JDBM and titanium al-
loy samples after incubation in PRP for 1 h had no signifi-
cant change, thus indicating the very high platelet compati-
bility of the JDBM alloy. The results generated herein con-
firm the hemocompatibility behavior of the JDBM alloy, 
and thereby suggests that the JDBM alloy is suitable for 
medical applications with respect to hemocompatibility.  
Collectively, the results from this study demonstrated 
that the JDBM alloy has excellent blood compatibility in 
vitro. However, there were some limitations to the current 
study. First, static in vitro tests may not exactly simulate the 
actual physiologic conditions in the human body because 
the human body fluid circulates dynamically. Moreover, ion 
concentrations differ in different parts of the human body 
[20]. In addition, experiments using human whole blood are 
needed to test the clinical applications of the JDBM alloy. 
Finally, although the novel JDBM alloy has excellent he-
mocompatibilities in vitro, further in vitro examinations and 
in vivo studies are necessary to validate and supplement the 
results of our study.  
4  Conclusion 
In the present study, the in vitro hemocompatibilities of the 
JDBM alloy were investigated to explore its potential as a 
degradable medical biomaterial. From the results of the 
current experiments, the JDBM alloy did not induce signif-
icant blood cell aggregation, platelet adhesion, and protein 
adsorption comparison with the titanium alloy (control). 
The results obtained from these investigations suggest that 
the JDBM alloy is a promising material for medical applica-
tions with respect to hemocompatibility.  
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